{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:51:26Z","timestamp":1762005086105,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002484","name":"Micron Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.diagmicrobio.2019.05.007","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T12:09:10Z","timestamp":1557835750000},"page":"114835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012\u20132016"],"prefix":"10.1016","volume":"96","author":[{"given":"Gregory G","family":"Stone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorgelina","family":"Smayevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystyna","family":"Kazmierczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Allergan Inc.","key":"10.1016\/j.diagmicrobio.2019.05.007_bb0005"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0010","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00257-10","article-title":"Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to \u03b2-lactam antibiotics","volume":"54","author":"Alvarez-Ortega","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0015","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of \u03b2-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0020","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1128\/AAC.01388-12","article-title":"On behalf of the Spanish Network for Research in Infectious Diseases (REIPI). Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones","volume":"56","author":"Cabot","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"year":"2015","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards. 10th ed. CLSI document M07-A10","author":"Clinical and Laboratory Standards Institute","key":"10.1016\/j.diagmicrobio.2019.05.007_bb0025"},{"year":"2016","series-title":"Performance standards for antimicrobial susceptibility testing: twenty-sixth informational supplement M100-S26","author":"Clinical and Laboratory Standards Institute","key":"10.1016\/j.diagmicrobio.2019.05.007_bb0030"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0035","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","article-title":"Diazabicyclooctanes (DBOs): a potent new class of non\u2013\u03b2-lactam \u03b2-lactamase inhibitors","volume":"14","author":"Coleman","year":"2011","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0040","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1473-3099(13)70168-3","article-title":"Spread of extremely resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study","volume":"13","author":"Edelstein","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0045","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0050","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1086\/432803","article-title":"National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by Gram-negative bacilli","volume":"41","author":"Gaynes","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0065","first-page":"2012","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: results from the INFORM global surveillance program","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0070","doi-asserted-by":"crossref","first-page":"e02569-17","DOI":"10.1128\/AAC.02569-17","article-title":"In vitro activity of imipenem\/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance program","volume":"62","author":"Karlowsky","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0075","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jgar.2018.07.012","article-title":"Activity of imipenem-relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotype from seven global regions \u2013 SMART 2015\u20132016","volume":"15","author":"Karlowsky","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0085","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1093\/jac\/dky267","article-title":"In vitro activity of ceftazidime-avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012\u20132015","volume":"73","author":"Kazmierczak","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0090","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1128\/AAC.02894-14","article-title":"Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against \u03b2-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa","volume":"58","author":"Keepers","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0095","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1128\/AAC.03057-14","article-title":"Avibactam and class C \u03b2-lactamases: mechanisms of inhibition, conservation of the binding pocket, and implications for resistance","volume":"58","author":"Lahiri","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0105","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"81","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0110","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-015-0926-5","article-title":"An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumoniae: impact of multidrug resistance","volume":"19","author":"Micek","year":"2015","journal-title":"Crit Care"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0115","first-page":"39","article-title":"Pseudomonas aeruginosa lifestyle: a paradigm for adaption and persistence","volume":"7","author":"Moradali","year":"2017","journal-title":"Front Cell Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0120","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkq306","article-title":"In vitro activity of ceftazidime + NXL104 against Pseudomonas aeruginosa and other non-fermenters","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2019.05.007_bb0125","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1128\/AAC.00220-16","article-title":"In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014)","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijantimicag.2017.09.016","volume":"51","author":"Pfaller","year":"2017","journal-title":"Int J Antimicrob Agents"},{"author":"Pfizer Pharmaceuticals","key":"10.1016\/j.diagmicrobio.2019.05.007_bb0055"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0135","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1128\/AAC.00574-09","article-title":"Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa","volume":"53","author":"Rodriguez-Martinez","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2019.05.007_bb0140","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistant patterns isolated in European hospitals (2011-12)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0145","doi-asserted-by":"crossref","first-page":"e02252-16","DOI":"10.1128\/AAC.02252-16","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility results from four years of the international network for optimal resistance monitoring program in the United States","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0150","doi-asserted-by":"crossref","first-page":"e01587-18","DOI":"10.1128\/AAC.01587-18","article-title":"Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. census divisions: results from the 2017 INFORM program","volume":"62","author":"Sader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0155","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijantimicag.2018.07.003","article-title":"In vitro activity of tigecycline and comparators (2014\u20132016) among key WHO \u2018priority pathogens\u2019 and longitudinal assessment (2004\u20132016) of antimicrobial resistance \u2014 a report from the T.E.S.T. study","volume":"54","author":"Seifert","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0160","first-page":"1396","article-title":"In vitro activity of ceftazidime\/avibactam against urinary isolates from patients in a phase 3 clinical trial programme for the treatment of complicated urinary tract isolates","volume":"72","author":"Stone","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0165","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1128\/AAC.01282-16","article-title":"Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant \u03b2-lactam resistance mechanisms","volume":"60","author":"Torrens","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumoniae, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.05.007_bb0175","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/AAC.04238-14","article-title":"Unexpected challenges in treating multidrug-resistant gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa","volume":"59","author":"Winkler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"year":"2018","author":"Wise","key":"10.1016\/j.diagmicrobio.2019.05.007_bb0180"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288931930166X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288931930166X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:53:04Z","timestamp":1760003584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073288931930166X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S073288931930166X"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.05.007","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012\u20132016","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114835"}}